title: Evaluation of Flibanserin: Science and Advocacy at the FDA.
authors.affiliation: Division of General Internal Medicine and Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania2Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
authors.forename: Walid F
authors.initials: WF
authors.lastname: Gellad
authors.affiliation: Department of Medicine and Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee.
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Flynn
authors.affiliation: Center for Drug Safety and Effectiveness and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland5Section of General Internal Medicine, Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland.
authors.forename: G Caleb
authors.initials: GC
authors.lastname: Alexander
mesh_terms: D026683:Advisory Committees; D001562:Benzimidazoles / Q000009:adverse effects / Q000266:history* / Q000627:therapeutic use; D003254:Consumer Advocacy / Q000266:history*; D003863:Depression / Q000188:drug therapy; D017277:Drug Approval / Q000266:history* / Q000379:methods; D005260:Female; D049674:History, 21st Century; D006801:Humans; D007989:Libido / Q000187:drug effects; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy / Q000266:history*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001562:Benzimidazoles; C098107:flibanserin